Abstract | BACKGROUND: STUDY METHODS: This was an observational analysis of all patients referred for TPE from 2018 to 2020 following laboratory confirmation of SFN with TS-HDS autoantibodies; a loading course of 3 to 5 procedures over 2 weeks was completed, with some patients returning for monthly procedures. The following data were collected: demographics, symptoms and duration, TS-HDS levels, skin biopsy results, reported responses to TPE, and TPE-associated adverse events. RESULTS: Of the 17 subjects, 12 (71%) were female and the mean age was 57.5 years (range 27-94). The most common reported symptom was lower extremity paresthesia (88% of subjects). The mean number of TPE procedures completed per subject was 9 (range 3-18), with 71% (12/17) reporting symptomatic improvement or slowed disease progression. About 15% of procedures were associated with an adverse event, with vasovagal reactions being the most common; 53% of patients had at least one adverse event. CONCLUSIONS: Given a reported symptomatic response rate of more than 70%, TPE may be a treatment option for individuals with autoimmune-mediated SFN associated with increased titers of TS-HDS IgM autoantibodies. Since TPE-associated adverse events appear common in this population, close monitoring during procedures is warranted.
|
Authors | Gregory M Olsen, Christopher A Tormey, Bertrand Tseng, Jeanne E Hendrickson, Nataliya Sostin |
Journal | Journal of clinical apheresis
(J Clin Apher)
Vol. 37
Issue 1
Pg. 13-18
(Feb 2022)
ISSN: 1098-1101 [Electronic] United States |
PMID | 34698404
(Publication Type: Journal Article, Observational Study)
|
Copyright | © 2021 Wiley Periodicals LLC. |
Chemical References |
- Disaccharides
- Immunoglobulin M
- Heparitin Sulfate
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Disaccharides
(immunology)
- Female
- Heparitin Sulfate
(immunology)
- Humans
- Immunoglobulin M
- Male
- Middle Aged
- Plasma Exchange
- Retrospective Studies
- Small Fiber Neuropathy
(immunology, therapy)
|